Toremifene is a first generation nonsteroidal selective estrogen receptor modulator used to treat certain breast cancers. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs.
- Mechanism
- Curator reviewed
Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors.
- Primary indication
- For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors.Curator reviewed · 2 structured indications
- Formula / weight
- C26H28ClNO · 405.96 g/mol (avg)
- First approval
- United States, 1997 · European Union, 2016
- Code names
- GTX-006 · J33.157K
- Brand names
Resolves to
XFCLJVABOIYOMF-QPLCGJKRSA-NSMILESCN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Toremifene, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account